1. Home
  2. HDL vs ABUS Comparison

HDL vs ABUS Comparison

Compare HDL & ABUS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

HDL

SUPER HI INTERNATIONAL HOLDING LTD. American Depositary Shares

HOLD

Current Price

$13.40

Market Cap

829.7M

ML Signal

HOLD

Logo Arbutus Biopharma Corporation

ABUS

Arbutus Biopharma Corporation

HOLD

Current Price

$4.56

Market Cap

848.8M

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
HDL
ABUS
Founded
2016
2005
Country
Singapore
United States
Employees
14003
N/A
Industry
Restaurants
Biotechnology: Pharmaceutical Preparations
Sector
Consumer Discretionary
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
829.7M
848.8M
IPO Year
N/A
2008

Fundamental Metrics

Financial Performance
Metric
HDL
ABUS
Price
$13.40
$4.56
Analyst Decision
Strong Buy
Analyst Count
0
1
Target Price
N/A
$5.00
AVG Volume (30 Days)
2.8K
1.2M
Earning Date
05-20-2026
05-14-2026
Dividend Yield
N/A
N/A
EPS Growth
N/A
55.26
EPS
N/A
0.87
Revenue
N/A
$14,083,000.00
Revenue This Year
$14.73
N/A
Revenue Next Year
$12.94
$239.71
P/E Ratio
$55.56
$5.28
Revenue Growth
N/A
128.21
52 Week Low
$13.11
$3.04
52 Week High
$21.21
$5.10

Technical Indicators

Market Signals
Indicator
HDL
ABUS
Relative Strength Index (RSI) 42.55 57.10
Support Level $13.31 $4.16
Resistance Level $15.21 $4.60
Average True Range (ATR) 0.24 0.18
MACD 0.03 0.04
Stochastic Oscillator 16.92 67.81

Price Performance

Historical Comparison
HDL
ABUS

About HDL SUPER HI INTERNATIONAL HOLDING LTD. American Depositary Shares

Super Hi International Holding Ltd is an investment holding company, and its subsidiaries are principally engaged in restaurant operations, delivery business, and sales of hot pot condiment products and food ingredients located in the overseas market outside Mainland China, Hong Kong, Macau, and Taiwan. Its mission is to become a world-wide integrated restaurant group, build the world's Chinese cuisine brand, and promote Chinese culinary heritage world-wide.

About ABUS Arbutus Biopharma Corporation

Arbutus Biopharma Corp is a clinical-stage biopharmaceutical company focused on infectious diseases. The company is leveraging its extensive virology expertise to identify and develop novel therapeutics with distinct mechanisms of action, which can be combined to provide a functional cure for patients with chronic hepatitis B virus (cHBV). Its pipeline of internally developed, proprietary compounds includes imdusiran (AB-729), a GalNAc-conjugated, subcutaneously delivered ribonucleic acid interference (RNAi) therapeutic, and AB-101, its proprietary oral PD-L1 inhibitor, for the treatment of chronic hepatitis B (cHBV). In addition, the company is also focused on maximizing the opportunity for its in-house developed Lipid Nanoparticle (LNP) delivery technology.

Share on Social Networks: